Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma

Bortezomib depended on PRDM1 and TP53 to exert therapeutic effect in activated B-cell-like diffuse large B-cell lymphoma

Bibliographic Details
Main Authors:	Jing Tang, Yue Li, Jiazhu Wu, Haorui Shen, Hua Yin, Jinhua Liang, Li Wang, Jianyong Li, Yi Xia, Wei Xu
Format:	Article
Language:	English
Published:	KeAi Communications Co., Ltd. 2024-03-01
Series:	Genes and Diseases
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352304223002039

Similar Items

P1155: MORE PRECISE RISK STRATIFICATION FOR TP53 MUTANT DIFFUSE LARGE B CELL LYMPHOMA
by: Kai-Xin Du, et al.
Published: (2023-08-01)

CLINICAL SIGNIFICANCE OF THE TP53 MUTATION STATUS IN DIFFUSE LARGE B-CELL LYMPHOMA
by: E. N. Voropaeva, et al.
Published: (2019-03-01)

Genotyping on circulating tumor DNA improves mutation detection rate in high-risk diffuse large B-cell lymphoma
by: Yi Xia, et al.
Published: (2024-07-01)

CASES OF DIFFUSE LARGE B-CELL LYMPHOMA WITH FUNCTIONAL INTRON MUTATIONS IN THE TP53 GENE
by: E. N. Voropaeva, et al.
Published: (2020-03-01)

Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma
by: Ying Fang, et al.
Published: (2023-10-01)

PB2385: CINOBUFAGIN PROMOTES APOPTOSIS OF DIFFUSE LARGE B LYMPHOMA CELLS BY INHIBITING UBIQUITINATION DEGRADATION OF TP53
by: Sanxiu He, et al.
Published: (2023-08-01)

Influence of <i>TP53</i> Mutation on Survival of Diffuse Large B-Cell Lymphoma in the CAR T-Cell Era
by: Edit Porpaczy, et al.
Published: (2021-11-01)

Identify truly high-risk TP53-mutated diffuse large B cell lymphoma patients and explore the underlying biological mechanisms
by: Du, K, et al.
Published: (2024)

Accurate interpretation of p53 immunohistochemical patterns is a surrogate biomarker for TP53 alterations in large B-cell lymphoma
by: Xinyi Li, et al.
Published: (2023-10-01)

TP53 mutations predict for poor survival in de novo diffuse large B-cell lymphoma of germinal center subtype
by: Zainuddin, Norafiza, et al.
Published: (2008)

P1220: EXPLORING TP53 BIOLOGY IN DIFFUSE LARGE B-CELL LYMPHOMA: A GENOMIC AND TRANSCRIPTOMIC META-ANALYSIS
by: Manik Uppal, et al.
Published: (2023-08-01)

α-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis
by: Yiqing Cai, et al.
Published: (2023-06-01)

PB2154: TP53 GENE MUTATION DIVERSITY IN RUSSIAN PATIENTS WITH B-CELL LYMPHOMAS
by: B. Biderman, et al.
Published: (2022-06-01)

Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib.
by: Shringarpure, R, et al.
Published: (2006)

A nomogram for predicting the rapid progression of diffuse large B‐cell lymphoma established by combining baseline PET/CT total metabolic tumor volume, lesion diffusion, and TP53 mutations
by: Cong Liu, et al.
Published: (2023-08-01)

Mutant TP53 driving the Warburg Effect in Mantle Cell lymphoma
by: Johannes Kliebhan, et al.
Published: (2022-10-01)

Impact of ARID1A and TP53 mutations in pediatric refractory or relapsed mature B-Cell lymphoma treated with CAR-T cell therapy
by: Yang Li, et al.
Published: (2023-11-01)

PB2378: COMPREHENSIVE ANALYSIS OF P53-RESPONSIVE MIRNA’S GENES METHYLATION, TP53 GENE MUTATIONS AND POLYADENYLATION SIGNAL DESTRUCTION IN DIFFUSE LARGE B-CELL LYMPHOMA TUMOR TISSUE.
by: Elena Voropaeva, et al.
Published: (2023-08-01)

Simultaneous Presence of Follicular Lymphoma, Diffuse Large B-cell Lymphoma, and Hodgkin-like Lymphoma
by: Alexandra Papoudou-bai, et al.
Published: (2018-11-01)

P1231: IMPACT OF ARID1A AND TP53 MUTATIONS IN PEDIATRIC REFRACTORY OR RELAPSED MATURE B-CELL LYMPHOMA TREATED WITH CAR-T CELL THERAPY
by: Qinlong Zheng, et al.
Published: (2023-08-01)

Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma
by: Xuzhao Zhang, et al.
Published: (2022-05-01)

Diffuse large B-cell lymphoma
by: Gatter, K, et al.
Published: (2010)

Cross-talk between Myc and p53 in B-cell lymphomas
by: Li Yu, et al.
Published: (2019-09-01)

Multiple primary malignancies in 788 Chinese patients with diffuse large B‐cell lymphoma
by: Xuchang Zhang, et al.
Published: (2023-07-01)

MicroRNA expression distinguishes between germinal center B cell-like and activated B cell-like subtypes of diffuse large B cell lymphoma.
by: Lawrie, C, et al.
Published: (2007)

P1177: PROGNOSTIC VALUE OF TP53 VARIANTS IN CHILDREN WITH MATURE B-CELL LYMPHOMA TREATED ACCORDING TO REDUCED-INTENSITY B-NHL-2010M PROTOCOL
by: V. Egor, et al.
Published: (2022-06-01)

Inflammatory Cells in Diffuse Large B Cell Lymphoma
by: Roberto Tamma, et al.
Published: (2020-07-01)

TP53 Mutations in Esophageal Squamous Cell Carcinoma
by: Leqi Zhong, et al.
Published: (2023-09-01)

Unraveling the enigma of B cells in diffuse large B-cell lymphoma: unveiling cancer stem cell-like B cell subpopulation at single-cell resolution
by: Fengling Liu, et al.
Published: (2023-12-01)

Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type
by: Valdemar Priebe, et al.
Published: (2020-07-01)

Insights into the Molecular Pathogenesis of Activated B-Cell-like Diffuse Large B-Cell Lymphoma and Its Therapeutic Implications
by: Georg Lenz
Published: (2015-05-01)

Refractory diffuse large B-cell Lymphoma
by: Hajar Masrour, et al.
Published: (2023-01-01)

Diffuse Large B Cell Lymphoma of the Breast
by: Feryal Karaca, et al.
Published: (2015-03-01)

Transplant in Diffuse Large B-Cell Lymphoma
by: Guilherme Duffles, et al.
Published: (2022-06-01)

A prognostic model based on gene expression parameters predicts a better response to bortezomib-containing immunochemotherapy in diffuse large B-cell lymphoma
by: Adrián Mosquera Orgueira, et al.
Published: (2023-04-01)

P1216: CD30 PROTECTS EBV-POSITIVE DIFFUSE LARGE B-CELL LYMPHOMA CELLS AGAINST MITOCHONDRIAL DYSFUNCTION THROUGH INCREASING BNIP3 EXPRESSION
by: Wei-Ting Wang, et al.
Published: (2023-08-01)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
by: Gurdip Singh Tamber, et al.
Published: (2021-11-01)

Constitutively active CaMKII Drives B lineage acute lymphoblastic leukemia/lymphoma in tp53 mutant zebrafish.
by: Sarah C Rothschild, et al.
Published: (2023-12-01)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
by: Melania Tesio
Published: (2023-02-01)

Vitreoretinal lymphoma followed by systemic diffuse large B cell lymphoma
by: Kenneth C. Fan, et al.
Published: (2019-06-01)